Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 Exposure vs Tumor Volume in Classical Hodgkin Lymphoma
2020-001856-16Phase 4Completed
- Sponsor
- CHU Rennes
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of nivolumab and pembrolizumab in classical Hodgkin lymphoma (cHL) and Hodgkin lymphoma (HL) (2 arms), sponsored by CHU Rennes. Primary endpoint: Primary: Correlation between initial TMTV and first-dose anti-PD-1 AUC. Started Jul 2020; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2020-001856-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001856-16.